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Abstract
Due to the diligence of inherent redundancy and robustness in many biological networks and pathways, multitarget
inhibitors present a new prospect in the pharmaceutical industry for treatment of complex diseases. Nevertheless, to design
multitarget inhibitors is concurrently a great challenge for medicinal chemists. We have developed a novel computational
approach by integrating the affinity predictions from structure-based virtual screening with dual ligand-based
pharmacophore to discover potential dual inhibitors of human Thymidylate synthase (hTS) and human dihydrofolate
reductase (hDHFR). These are the key enzymes in folate metabolic pathway that is necessary for the biosynthesis of RNA,
DNA, and protein. Their inhibition has found clinical utility as antitumor, antimicrobial, and antiprotozoal agents. A druglike
database was utilized to perform dual-target docking studies. Hits identified through docking experiments were mapped
over a dual pharmacophore which was developed from experimentally known dual inhibitors of hTS and hDHFR.
Pharmacophore mapping procedure helped us in eliminating the compounds which do not possess basic chemical features
necessary for dual inhibition. Finally, three structurally diverse hit compounds that showed key interactions at both active
sites, mapped well upon the dual pharmacophore, and exhibited lowest binding energies were regarded as possible dual
inhibitors of hTS and hDHFR. Furthermore, optimization studies were performed for final dual hit compound and eight
optimized dual hits demonstrating excellent binding features at target systems were also regarded as possible dual
inhibitors of hTS and hDHFR. In general, the strategy used in the current study could be a promising computational
approach and may be generally applicable to other dual target drug designs.
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Introduction
Drug design is the inventive process of finding new medications
based on the knowledge of the biological target. The notion of ‘one
molecule – one target – one disease’ has been a prevalent
paradigm in pharmaceutical industry. The main idea of this
approach is the identification of a single protein target whose
inhibition leads to a successful treatment of the examined disease.
The predominant assumption is that highly selective ligands would
avoid unwanted side effects caused by binding to secondary non-
therapeutic targets. Many successful drugs have been transpired
from this procedure. However, the diligence of inherent re-
dundancy and robustness in many biological networks and
pathways depicts that inhibiting a single target might fall short
of producing the desired therapeutic effect [1–3]. As simultaneous
intervention of two or multiple targets relevant to a disease has
shown improved therapeutic efficacy, there has been a move
toward multiple target drugs [4]. Across the pharmaceutical
industry, this strategy of multitarget drugs has become an active
field and around 20 multitarget drugs have been approved or are
in advanced development stages [5]. Multitarget therapeutic
strategy can be used to inhibit two or more enzymes, act on an
enzyme and a receptor, or affect an ion channel and a transporter.
Multitarget therapeutic strategy can be accomplished by one of the
following approaches: (i) acting upon different targets to create
a combination effect (e.g., Bactrim, which acts on two targets in
the folate biosynthesis pathway in bacteria), (ii) altering the ability
of another to reach the target, and (iii) binding the different sites
on the same target to create a combination effect [6]. Modulating
multiple targets in the biological network simultaneously is
renowned to be beneficial for treating a range of diseases, such
as acquired immune deficiency syndrome (AIDS), atherosclerosis,
cancer, and depression, and this recognition has escorted to
a growing tendency to devise multiple-target drugs [7–9]. Several
multicomponent drugs have been launched, such as
(4 S,7 S,10a S)-5- oxo-4-{[(2 S)-3-phenyl-2-sulfanylpropanoyl]a-
mino}-2,3,4,7,8,9,10,10a-octahydropyrido[6,1-] [1,3]thiazepine-
7-carboxylic acid (omapatrilat) (a dual angiotensin-converting
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enzyme and neutral endopeptidase inhibitor) and 5-((6-((2-
fluorophenyl) methoxy)-2-naphthalenyl) methyl)-2,4-thiazolidine-
dione (netoglitazone) (a peroxisome proliferator-activated receptor
(PPAR)-R and PPAR-c agonist) [10]. Many multitarget drugs are
in clinical use today, but the discovery process is serendipitous, and
their modes of action are usually elucidated retrospectively.
Although, there is an increasing interest in developing drugs that
take effect on multiple targets but designing multitarget inhibitors
with predefined biological profiles is concurrently a great challenge
for medicinal chemists. A very few computer-aided multitarget
methods have been introduced in designing multitarget drugs. For
instance, early design strategies tried to link the pharmacophores
of known inhibitors; however these methods often lead to high
molecular weight and low ligand efficacy. Moreover, sequential
docking has also been implemented in designing multitarget drugs
[11]. However, this docking methodology is computationally
expensive for large-scale database screening. Another computa-
tional methodology merging molecular docking with common
pharmacophore mapping was also applied for design of multi-
target drugs. But, this approach used a single conformation
inhibitor-protein complex [12]. Thus, more effective computa-
tional methods for the identification and further optimization of
multitarget drugs in a complex disease system are needed.
Drug discovery and development is a lengthy and costly process.
Of special interest to us are the development and application of
novel computational methods for lead generation and lead
optimization in the drug discovery process. These computational
methods are generally categorized as ligand-based and structure-
based methods [13]. The uses of structure-based and ligand-based
methods with rational drug discovery have been fairly separate
approaches. Moderate resolution (at least 2.4 Å) three dimensional
X-ray structures of drug targets are a prerequisite for structure-
based drug design. These structures provide a starting point for
rational drug design by defining the topography of the protein
target that the ligand surface must complement. This information
helps the synthetic chemist to optimize compounds so as to
enhance their interactions with the protein, resulting in improved
potency and selectivity). Indeed, there are now several drugs on
the market that originated from this structure-based design
approach. The most commonly cited are the human immunode-
ficiency virus (HIV) drugs, such as amprenavir (Agenerase) and
nelfinavir (Viracept), which were developed using the crystal
structure of HIV protease [14]. Moreover, designed according to
information obtained from the crystallographic data of the viral
NA complexed with its natural substrate sialic acid, zanamivir and
oseltamivir present a big success in the history of rational,
structure-based drug development [15]. Ligand-based computa-
tional methods are often employed when detailed structural
information is not available for the target of interest, or the
biological target is completely unknown as is the case in many
phenotypic assay based discovery. When biological activities of
multiple hits are known, a more sophisticated class of computa-
tional techniques known as pharmacophore identification methods
is often employed to deduce the essential features required for the
biological activity. The description of important chemical features
in the shape of a pharmacophore model offers the advantage of
a fast and reliable technique when the input data is of high quality
(high affinity ligands, high resolution of the X-ray complex
structure).
Keeping this in view, a new strategy amalgamating structure-
based and ligand-based approaches to identify small molecules
modulating multiple targets is presented in this research exertion.
This strategy integrates the structure-based information about the
key elements in protein-ligand binding with the dual ligand-based
pharmacophore model derived from experimentally known dual
inhibitors to design multitarget drugs. On one hand, the structure-
based approach is able to present the interactions of a ligand to the
target protein in a very specific way. On the other hand, the
ligand-based pharmacophore modeling approach is not restricted
to the bound conformation of the ligand in the crystalline complex
and is also able to reveal the common demand of multiple ligands.
Thymidylate synthase (TS) (EC 2.1.1.45) and Dihydrofolate
reductase (DHFR) (EC 1.5.1.3) are the key enzymes in folate
metabolic pathway that is necessary for the biosynthesis of RNA,
DNA, and protein [16,17]. TS catalyzes the dUMP (2̀-deoxyur-
idine-5̀-monophosphate) methylation reaction involving a concert-
ed transfer and the reduction of a single carbon with concomitant
production of dTMP (thymidylate monophosphate) (one of the
four building blocks of DNA) and dihydrofolate (DHF) (Figure 1).
As, the reaction of TS is the sole intracellular source of de novo
synthesized dTMP, therefore, inhibition of TS blocks DNA
synthesis and prevents cellular proliferation [18]. For continuous
production of dTMP in dividing cells, the oxidized 7,8-DHF must
be converted back to 5,10-methylenetetrahydrofolate. Dihydrofo-
late reductase (DHFR) 5 catalyzes first of the two steps in this
biotransformation in which NADPH acts as the source of the
reductant. DHF is reduced to tetrahydrofolate (THF) via DHFR.
DHFR is present in all cells and is necessary for the maintenance
of intracellular folate pools in a biochemically active reduced state.
Inhibition of DHFR results in depletion of intracellular reduced
folates, which are necessary for one-carbon transfer reactions.
One-carbon transfer reactions are important for the biosynthesis
of thymidylate, purine nucleotides, methionine, serine, glycine,
and many other compounds necessary for RNA, DNA, and
protein synthesis [19–21]. The inhibition of DHFR depletes THF
pools, causing genomic and proteomic instability and, ultimately,
cell death. Consequently, targeting of both TS and DHFR for
inactivation in tumor cells is an imperative approach in developing
drugs for cancer chemotherapy. Several TS and DHFR inhibitors,
as separate entities, have found clinical utility as antitumor agents
[22–25]. One of the potent TS inhibitors, a dUMP analogue 5-
fluoro-dUMP (FdUMP), is an active metabolite of a broadly used
anticancer drug, 5-fluorouracil (5-FU). The DHFR inhibitor
methotrexate (MTX) is one of the first chemotherapeutic agents
discovered and is still a mainstay in single agent and combination
cancer chemotherapy [26]. It has been reported that when
a DHFR inhibitor is used in combination with a TS inhibitor,
synergistic growth inhibition can occur against Lactobacillus casei,
rat hepatoma cells, and human lymphoma cells [27,28]. Inhibition
of TS or of DHFR leads to ‘‘thymineless death’’ in the absence of
salvage, and inhibition of these enzymes has found clinical utility
as antitumor, antimicrobial, and antiprotozoal agents [17,19,20].
Dual inhibitors of TS and DHFR inhibitors could circumvent the
pharmacokinetic disadvantages of two separate drugs. Therefore,
to design single agents that could act as dual inhibitors of TS and
DHFR is an important strategy in developing drugs for cancer
chemotherapy.
Materials and Methods
Preparation of the Docking Library
Maybridge, a commercial chemical database containing 59 652
compounds, has been employed in this study for structure-based
virtual screening procedure [29]. However, this database is found
to have a number of nondruglike compounds. As, it is worthless to
dock all the compounds of this database into the active site of
protein target and then reject them in the later stage for their
nondruglike properties, the compounds not satisfying druglike
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properties were excluded from the database prior to molecular
docking (structure-based virtual screening). In order to accomplish
this task, compounds in the database were subjected to various
scrupulous druglike filters such as Lipinski’s rule of five and
ADMET (absorption, distribution, metabolism, excretion, and
toxicity) properties. Prepare Ligands and ADMET Descriptors proto-
cols as available in Accelrys Discovery Studio v3.0 (DS), Accelrys,
San Diego, USA program were used in this step.
Preparation of Target Protein Systems for Docking
The necessity of providing a correct representation of the
protein structure is a prerequisite for carrying out a successful
docking study. Hence to ensure quality, the following aspects were
considered. In this study, we have used the crystal structure of
human DHFR (PDB ID: 1U72) determined at a resolution of
1.9 Å bound with inhibitor molecule Methotrexate (MTX) [30].
While, crystal structure with PDB ID of 1HVY co-crystallized with
potent inhibitor TOMUDEX at a resolution of 1.9 Å was used for
human TS enzyme [31]. The 3D coordinates of these enzymes
were obtained from PDB and all the water molecules present in
the structure of proteins were removed. Hydrogen atoms were
added to the target protein structures using CHRAMM force field
as available in DS followed by the minimization of added
hydrogen atoms using Smart Minimizer protocol with a constraint
on heavy atoms. The resulting target protein structures were used
in molecular docking studies.
Molecular Docking for hDHFR and hTS Inhibition
Virtual screening is emerging as a productive and cost-effective
technology in rational drug design for the identification of novel
lead compounds from large virtual database. In this study, a locally
constructed druglike Maybridge database having a huge set of
diverse compounds was used for docking into the active sites of
hTS and hDHFR enzymes. Molecular docking studies were
carried out using GOLD (Genetic Optimization for Ligand
Docking) 5.1 program from Cambridge Crystallographic Data
Center, UK. GOLD uses a genetic algorithm for docking ligands
into protein binding sites to explore the full range of ligand
conformational flexibility with partial flexibility of protein [32].
Molecular docking was performed to generate the bioactive
binding poses of compounds in the active site of both enzymes. For
both target systems, the active site was defined with a 10 Å radius
around the ligand present in the corresponding crystal structure.
Ten docking runs were performed per structure unless five of the
10 poses were within 1.5 Å RMSD of each other. All other
parameters were kept at their default values. The GOLD fitness
score is calculated from the contributions of hydrogen bond and
van der Waals interactions between the protein and ligand,
intramolecular hydrogen bonds and strains of the ligand. The
interacting ability of a compound depends on the fitness score,
greater the GOLD fitness score better the binding affinity. The
protein–ligand interactions were examined by DS. Compounds
which showed the key interactions with critical amino acids
present in the active site of both target proteins and also exhibited
higher GOLD fitness score were considered as possible dual hits
and were selected for further evaluation.
Generation and Validation of Common Feature
Pharmacophore Model
Several scientific resources were searched for the compounds
with the experimentally known dual inhibition for hTS and
hDHFR. This survey revealed that folate analogue with 2-
amino-4-oxo or 2-methyl-4-oxo substitution in the pyrimidine
ring is considered important for potent TS inhibitory activity,
for example, the clinically used pemetrexed (PMX) and
raltiterxed (RTX) [18,22]. In contrast, folate analogues that
inhibit DHFR generally contain 2,4-diamino substitution in the
pyrimidine ring for potent DHFR inhibitory activity, typified by
methotrexate (MTX), a DHFR inhibitor that has been
a mainstay in cancer chemotherapy [26]. Accordingly, five
diverse and experimentally known potent dual inhibitors of hTS
and hDHFR with these chemical moieties in their structures
were selected as training set and were employed in common
feature pharmacophore generation calculation (Figure 2) [33–
36]. Maximum omit feature value of 0 was assigned to all
compounds in the training set. Energy minimization process was
performed with CHARMM forcefield for all the compounds in
training set. Poling algorithm was applied to generate a maxi-
mum of 255 diverse conformations with the energy threshold of
20 kcal mol-1 above the calculated energy minimum for every
compound in the dataset. These conformers were generated
using Diverse Conformer Generation protocol running with Best/
Flexible conformer generation option as available in DS. All five
training set compounds associated with their conformations were
used in common feature pharmacophore generation. HipHop
module of the catalyst which was popularly known for Common
Feature Pharmacophore Generation is available in DS as
Common Feature Pharmacophore Generation protocol. This protocol
was used to develop pharmacophore model. Feature Mapping
protocol was used to identify common features shared by
a training set. As predicted, hydrogen bond acceptor (HBA),
hydrogen bond donor (HBD) and hydrophobic aromatic
(HY_AR) features were selected during the pharmacophore
generation. Each hypothesis generation run returns 10 possible
pharmacophore hypotheses having a different arrangement of
constituent features and sorts them according to the ranking
scores. Redundant hypotheses that have the same chemical
characteristics and nearly the same distances between these
functions were deleted. The hypothesis with diverse configura-
tion was selected as final model according to ranking scores and
best fit values. The reliability of the generated pharmacophore
model was validated on the basis of presence of chemical
features essential to interact with the key amino acids in the
active sites of target proteins.
Figure 1. Conversion of deoxyuridine monophosphate (dUMP)
into deoxythymidine monophosphate (dTMP), and dihydrofo-
late (FH2) to tetrahydrofolate (FH4) by TS and DHFR, re-
spectively.
doi:10.1371/journal.pone.0060470.g001
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Ligand Pharmacophore Mapping
The hit compounds obtained from the molecular docking
experiments performed both for the hTS and hDHFR with
druglike Maybridge database are used in this study along with the
pharmacophore model generated for hTS and hDHFR. Ligand
Pharmacophore Mapping protocol as implemented in DS is used to
map all the hit compounds upon the generated pharmacophore
model with the Best Flexible Search option. The compounds that
mapped well on the pharmacophore model were selected as
possible hits for dual inhibition and were utilized for their further
validation through their binding energy calculations using
AutoDock.
Molecular Docking Study Using Autodock 4.2
Autodock 4.2 was used to calculate the binding energies of the
possible hits along with training set compounds at the active sites
of both hTS and hDHFR enzymes. As no scoring function
employed in currently available docking programs performs better
for all macromolecular targets, a combination of scoring functions
from various programs (GOLD and AutoDock in this study) may
provide significant value in predicting favorable binding con-
formations. Binding energies of the selected possible dual hits were
calculated using AutoDock as a cross-validation to the GOLD
predictions. AutoDock consumes more calculation time yet
envisages the binding conformations more precisely [37]. It also
computes torsional energy which gives rise to the binding energy
of the docked compound. The starting proteins for hTS and
hDHFR were prepared from their high resolution crystal
structures (PDB ID: 1HVY for hTS, PDB ID: 1U72 for hDHFR)
deposited in the Protein Data Bank. Possible dual hits along with
the training set compounds were docked using the Lamarckian
genetic algorithm (LGA) in the ‘‘docking active site’’, defined
through a grid centered on the ligand of the complex structure.
Population size of 150, mutation rate of 0.02, and crossover rate of
0.8 were set as the parameters. The default grid spacing (0.375 Å)
was used. Simulations were performed using up to 2.5 million
energy evaluations with a maximum of 27 000 generations. Each
simulation was performed 10 times, yielding 10 docked conforma-
tions. The lowest energy conformations were regarded as the
binding conformations between ligands and the protein.
Optimization Studies
One of the final hit compounds was used as lead for further
optimization. Various substitutions were made at its side chains.
These optimized compounds were also subjected to map
pharmacophore model which is generated from experimentally
known potent dual inhibitors of hTS and hDHFR enzymes.
Moreover, molecular docking experiments using both GOLD and
AutoDock programs were also performed for these optimized
compounds. Synthetic accessibility scores for all the optimized
compounds were used to validate the synthetic possibilities.
SYLVIA v 1.0 program from the Molecular Networks group
was employed to calculate the synthetic accessibility of these
optimized compounds [38,39]. The estimation of synthetic
accessibility using SYLVIA provides a number between 1 and
10 for compounds that are very easy to synthesize and compounds
that are very difficult to synthesize, respectively. The method for
calculating synthetic accessibility takes account of a variety of
criteria such as complexity of the molecular structure, complexity
of the ring system, number of stereo centers, similarity to
Figure 2. Training set compounds used in common feature pharmacophore generation.
doi:10.1371/journal.pone.0060470.g002
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commercially available compounds, and potential for using
powerful synthetic reactions. These criteria have been individually
weighted to provide a single value for synthetic accessibility.
Result and Discussion
Strategy for Designing Dual Inhibitors
Computer-based virtual screening is a quite useful tool in drug
design as it is a cost-effective and time saving process. Virtual
screening methods can be divided into two broad categories:
structure-based, and ligand-based. In case, the three-dimensional
(3D) structure of the target receptor or of its binding site is
available, docking is a highly effective technique for virtual
screening. The pharmacophore model which is an interpretation
of the interaction between a receptor and a ligand is also clearly
established as one of the successful computational tools in rational
drug design. When a set of active ligands is available, it is possible
to compute their shared pharmacophore. Keeping this in view,
a new strategy integrating structure-based and ligand-based
approaches to identify small molecules modulating multiple targets
is presented in this study. This strategy merges the structure-based
information about the key elements in protein-ligand binding with
the dual ligand-based pharmacophore model derived from
experimentally known dual inhibitors for design of multitarget
drugs.
Our strategy (Figure 3) to discover dual target inhibitors starts
from the preparation of a druglike database which is further
docked into the active site of one of the target proteins thus
predicting the binding conformations and molecular interactions
of small molecules of database. On the basis of the binding mode
analysis, compounds with good binding characteristics and
showing strong interactions with key amino acids at the active
site of first protein target were chosen for further processing. In
next step, selected compounds were docked into the active site of
the second protein target in order to examine their binding affinity
for this protein. The binding modes of all the docked compounds
were analyzed for their molecular interactions at the active site.
The compounds showing strong key interactions at the active site
were considered as possible dual hits and were chosen for the next
step. After the completion of protein-based virtual screenings, in
the third step of dual inhibition process, a common feature
pharmacophore model was developed from experimentally known
dual inhibitors of both the target proteins. Fourth step involves the
mapping of docking hits of both target proteins over the derived
pharmacophore model in order to find out, whether these hit
compounds possess the very basic chemical features which are
present in currently available dual inhibitors of hTS and hDHFR,
and whether their binding conformations accommodate the
common pharmacophore. Moreover, mapping also helped us to
evade the difficulty stemmed from overestimation of the affinity of
weak binders producing false positives during docking studies. The
compounds scoring the best fit values were docked again to the
active site of both the target proteins using another molecular
docking program AutoDock to check the binding energies of
chosen compounds at the active sites of hTS and hDHFR. Finally,
compounds that bind strongly at both the active sites, fit well upon
the dual ligand-based pharmacophore model, and exhibit lowest
binding energies were regarded as final hits for dual inhibition of
hTS and hDHFR. After the selection of final possible dual
inhibitors for hTS and hDHFR enzymes, one of the final hits was
used as lead for further optimization. The complete strategy
followed in this study was also repeated for the optimized
compounds to ensure that the optimized hits really fit the
generated pharmacophore model and active sites of both the
targets.
Molecular Docking of Druglike Database for Target
Proteins
Maybridge database containing 59 652 compounds was used for
docking into the active sites of hTS and hDHFR enzymes. Prior to
protein-based virtual screening experiments, this database was
transformed to druglike databases by Prepare Ligands and ADMET
Descriptors protocols of DS. Prepare Ligands protocol eradicated the
duplicate structures, fixed bad valencies, and calculated 3D
coordinates of all the compounds. ADMET Descriptors protocol
calculated various properties such as aqueous solubility, blood
brain barrier penetration, CYP2D6 binding, hepatotoxicity,
intestinal absorption, and plasma protein binding. Calculating
ADMET descriptors early in the development of a drug is
important to avoid elimination of compounds with unfavorable
ADMET characteristics later in the drug development process.
Finally, 4966 druglike compounds were selected and were applied
subsequently in protein-based virtual screening. The druglike
database was docked at the active site of preprocessed protein
structure of hDHFRF using GOLD. The experimentally known
dual inhibitors of hTS and hDHFR present in the training set were
also docked with the same parameters used in database docking.
Compound 1 which showed maximum inhibition activity against
hDHFR, has scored a GOLD fitness score of 76.448 along with
the strong molecular interactions with the key active site residues.
The 73 hit compounds from the druglike database scored a GOLD
fitness score greater than 70 and were selected for further docking
experiment with second target protein hTS. The docking of these
73 possible hDHFR inhibitors along with the training set
compounds at the active site of hTS was performed and docking
results were evaluated. Compound 2 of training set which showed
maximum inhibition activity against hTS, scored GOLD fitness
score of 78.220. The scrutiny of bonding conformations of docked
hit compounds showed that 32 out of 73 compounds showed
GOLD fitness score greater than 70 and also formed strong
interactions with active site of enzyme. Thus, these 32 compounds
were selected as final leads for further processing in dual inhibition
strategy.
Generation and Selection of a Common Feature
Pharmacophore Model for Inhibition of hTS and hDHFR
Common feature pharmacophore model was generated for the
target proteins using a set of experimentally known dual inhibitors
of hTS and hDHFR. With the aim of acquiring a best model,
numerous common feature pharmacophore generation runs were
performed by altering the parameters such as minimum inter-
feature distance values, maximum omit feature, and the permu-
tation of pharmacophoric features. The qualitative top ten
pharmacophore models were developed (Table 1) using Common
Feature Pharmacophore Generation/DS to identify the common features
necessary to inhibit both hTS and hDHFR enzymes. Direct and
partial hit mask value of ‘19 and ‘09 for models connoted that the
compounds present in dataset were well mapped to all the
chemical features in the models and there is no partial mapping or
missing features. The Cluster analysis was used to evaluate and
categorize the difference between the compositions of models’
chemical features and locations. These models could be roughly
classified into two clusters according to the pharmacophoric
features presented. The models in cluster I identified five
functional features, including three HBA, one HBD, and one
HY_AR feature. The models in cluster II also recognized five
Strategy for Dual Inhibitor Design
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s
functional features, with three HBA, one HBD, and one ring
aromatic (RA). A closer scrutiny of the pharmacophore models in
each cluster revealed subtle discrepancy among models. The
distances between some pharmacophoric features in all models
were rather constant, whereas some distances fluctuated in
a relatively broad range, which indicated divergent tolerance of
Figure 3. Strategy of dual inhibitor discovery employed in this study.
doi:10.1371/journal.pone.0060470.g003
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different features to spatial variation and provided rationale for
further structural modification and optimization. The top two
models in cluster I showed comparatively higher ranking score and
best fit values of the training set compounds, therefore, these two
models were further evaluated to find the best model. These
pharmacophore models have scored same ranking score; there-
fore, an analysis of the best fit values of the training set compounds
was carried out to choose the best model. The calculated best fit
values designated Model 1 as the best and final dual ligand-based
pharmacophore model (Dual_Pharma) (Figure 4A). This final
Dual_Pharma which consists of three HBA, one HBD, and one
HY_AR feature was further overlaid on the most active compound
of training set (Figure 4B). The most active compound 1 could
map all the features of the Dual_Pharma, with a fit value of 4.99.
Comparison with the Models of Literature
Our dual ligand-based pharmacophore model is in agreement
with the information provided by the former studies. The
importance of HBA and HBD is confirmed for DHFR and TS
inhibition. Moreover, presence of hydrophobic aromatic features
is also considered significant for inhibition of DHFR and TS
enzymes [40–42].
Validation of Common Feature Pharmacophore Model
The purpose of the pharmacophore validation is to appraise the
quality of a pharmacophore model. The reliability of the
Dual_Pharma developed from the dual inhibitors of hTS and
hDHFR was validated on basis of the existence of chemical
features crucial to interact with the important amino acids in the
active sites of both target proteins. To find out the existence of
chemical features that are complementary to the active site of
hDHFR enzyme, one of the training set compounds was overlaid
on Dual_Pharma and its binding conformation was generated
from the molecular docking process. Furthermore, ligand in-
teraction diagram was generated for the hDHFR-inhibitor
complex by using DS which illustrated the amino acids
complemented to every feature present in the pharmacophore
model (Figure 5). Dual_Pharma consists of three HBA, one HBD,
and one HY_AR feature. Overlay of the bound inhibitor on
Dual_Pharma connoted that chemical features of pharmacophore
model were located in such a way that HY_AR feature was found
to make important hydrophobic contact with Phe31 which is
considered an essential amino acid for DHFR inhibition
[33].Moreover, orientation of HBD feature in the binding site
made it possible that it could interact with essential residues like
Ile60, Asp21, and Leu22. While, all three HBA features were
positioned in such a manner that instigated interactions with
residues like Val115, Tyr121, Ala9, and Thr56 and others at the
active site region of hDHFR. In case of hTS enzyme, ligand
interaction diagram was also generated for the hTS-inhibitor
complex which manifested that HBA features were able to form
imperative interactions with key residues like Asp218, Arg50,
Tyr258, and Ser216 (Figure 6). The HY_AR and HBD features
also showed important contacts with Trp109, Ile108, and His196
[43].Thus, these annotations associated with the features present
in the developed pharmacophore model compared with the
interaction spots at the active site regions of hTS and hDHFR
have denoted the importance of the generated dual pharmaco-
phore for having the very basic chemical features necessary for
inhibition of both target proteins.
Ligand Pharmacophore Mapping and Identification of
Final Dual Hits
The hit compounds obtained from the molecular docking
experiments of hTS and hDHFR are employed in this procedure
Figure 4. Generated pharmacophore model (Dual_Pharma) along with its interfeature distance (A), and its overlay on compound 1
of the training set (B).
doi:10.1371/journal.pone.0060470.g004
Table 1. Summary of the Dual Pharmacophore Models








Hypo1 ZDAAA 88.594 11111 00000 5
Hypo2 ZDAAA 88.594 11111 00000 5
Hypo3 ZDAAA 88.438 11111 00000 5
Hypo4 RDAAA 88.257 11111 00000 5
Hypo5 RDAAA 88.257 11111 00000 5
Hypo6 RDAAA 88.257 11111 00000 5
Hypo7 RDAAA 88.257 11111 00000 5
Hypo8 ZDAAA 88.196 11111 00000 5
Hypo9 ZDAAA 88.196 11111 00000 5
Hypo10 ZDAAA 87.933 11111 00000 5
doi:10.1371/journal.pone.0060470.t001
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along with the pharmacophore model developed from dual
inhibitors of hTS and hDHFR. In order to find out the presence
of features which are imperative for strong enzyme-ligand binding
interactions for both enzymes in the hit compounds, the binding
conformations of the 32 hit compounds which scored GOLD
fitness score over 70 for each target protein were mapped over the
validated Dual_Pharma using Ligand Pharmacophore Mapping pro-
tocol of DS. Out of 32 hits, three structurally diverse hit
compounds that mapped well on the developed pharmacophore
model, showed key interactions with the active site residues, and
also scored highest GOLD docking score for both target enzymes
were selected as final hits for dual inhibition of hTS and hDHFR
(Table 2).
In order to further validate the performance of docking
procedure, database screening process was performed using
common feature pharmacophore model labeled as Dual_Pharma.
Overall, 14 compounds of druglike Maybridge database mapped
the features of Dual_Pharma. Three final hits were also among
these 14 compounds retrieved by Dual_Pharma through database
screening process. However, when GOLD docking score of newly
retrieved 11 compounds was checked, it showed much less score
for both targets as compared to final three hits. Thus, the result of
this database screening process further validated the good
performance of docking procedure in identifying potentially
potent dual inhibitors of hTS and hDHFR.
The 2D structures of final three hits ML00100, SPB07954, and
HTS07361 along with their mapping over Dual_Pharma are
shown in Figure 7. These final dual hits were utilized for their
further validation as potential dual inhibitors through computation
of their binding affinity for the target proteins via another
molecular docking study using AutoDock.
Molecular Docking Study Using Autodock 4.2
The binding energies of the final hits along with training set
compounds were calculated at the active sites of both hTS and
hDHFR enzymes as a cross-validation to the GOLD predictions.
AutoDock 4.2 is based on a Lamarckian genetic algorithm (LGA)
method. Basically, this program determines total interaction
energies between random pairs of ligands and various selected
portions of protein to determine docking poses. Final three hits
along with the training set compounds were docked using LGA in
the ‘‘docking active site’’, defined through a grid for hTS and
hDHFR. Although, AutoDock consumes more calculation time
yet envisages the binding conformations more precisely. In case of
hTS enzyme, Autodock docking results showed that all the three
final hits have gained better binding energy values compared to
Figure 5. Ligand-protein interaction diagram of hDHFR-inhibitor complex (compound 1 in the training set). The pharmacophore
mapping of the same compound is also illustrated. HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; HY_AR, hydrophobic aromatic. The
locations of amino acid residues are represented in rectangular boxes, where pink and green colors denote both the hydrogen bond acceptor/donor
and nonpolar contacts, respectively.
doi:10.1371/journal.pone.0060470.g005
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the binding energies of experimentally known potent dual
inhibitors of the training set. Moreover, Autodock docking of the
final hit compounds for hDHFR also showed better or similar
binding energies compared to the training set compounds. Thus,
upshots of Autodock docking study not only validate the GOLD
predictions but also envisage the three final hits for possible dual
inhibition of TS and DHFR.
Binding Modes of the Identified Hits
Compound 1 and compound 2 of the training set which showed
potent activity for hDHFR and hTS, respectively, were analyzed
for their binding modes and the molecular interactions. Com-
pound 1 was considered as reference to evaluate the binding
modes of the final dual hits at the active site of hDHFR. This
compound has formed hydrogen bond interactions with key
residues like Ile7, Val115, Asn64, and Tyr121 (Figure 8A).
Moreover, very important p…p interactions between compound 1
and key residues Phe31and Phe34 were also observed. Compound
2 has shown interactions at the active site of hTS with key residues
including Arg50, Trp109, Asp218, and Tyr258. This compound
was used as standard compound for binding mode analysis of final
hits at hTS active site (Figure 8C). Molecular overlay of final three
hits at the active sites of hTS and hDHFR with compounds 1 and
2 is depicted in Figure 8. As, several crystal structures of hDHFR
and hTS enzymes complexed with various inhibitors are presented
in the literature, therefore, molecular interactions between the
target protein systems and the diverse inhibitors were also
scrutinized from the ligplot figures accessible through the
PDBSum database for further validation of the binding modes
of final dual hit compounds.
Figure 6. Ligand-protein interaction diagram of hTS-inhibitor complex (compound 2 in the training set). The pharmacophore mapping
of the same compound is also illustrated. HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; HY_AR, hydrophobic aromatic. The locations of
amino acid residues are represented in rectangular boxes, where pink and green colors denote both the hydrogen bond acceptor/donor and
nonpolar contacts, respectively.
doi:10.1371/journal.pone.0060470.g006
Table 2. GOLD Fitness Scores and AutoDock Binding Energies of Final Possible Dual Inhibitors of hTS and hDHFR.
hTS Binding hDHFR Binding
Compound GOLD Fitness Score Binding Energy (kcal/mol) GOLD Fitness Score Binding Energy (kcal/mol)
ML00100 83.743 26.32 78.506 26.77
SPB07954 81.509 25.78 76.042 26.02
HTS07361 82.372 26.17 72.698 27.03
doi:10.1371/journal.pone.0060470.t002
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Binding Mode of ML00100
The binding modes of ML00100 within the active sites of hTS
and hDHFR have been elucidated. For hTS, this compound has
scored a GOLD fitness score of 83.743 and has demonstrated
interactions with the key residues like Trp109, Arg50, Asp215,
Ser216, Asp218, Gly222, and Tyr258 (Figure 9). The meticulous
analysis of binding conformation of ML00100 in the binding
pocket of hTS revealed that1,4-dimethoxybenzene ring is making
important hydrophobic contact with Trp109. Previous study has
also indicated that this kind of interaction with Trp109 enhances
the potent inhibitory activity against hTS [35]. Furthermore,
various close contacts between the oxygen atoms of sulfonyl group
and Arg50 (2.778 Å, 3.152 Å) were observed. The nitrogen atoms
of ML00100 compound also formed hydrogen bonds with the
important residues like Arg 215, Asp218 (2.169 Å, 2.644 Å),
Gly222 (3.389 Å), and Tyr258 (3.668 Å). For hDHFR, this
compound has scored a GOLD fitness score of 78.506 and has
shown interactions with the important residues including Leu22,
Phe31, Asn64, Val115, and Tyr121. The 1,4-dimethoxybenzene
ring of the ML00100 has established imperative p…p interactions
with Phe31 in the binding pocket of hDHFR. This key interaction
has significant role in driving the hit compound to adopt an
appropriate bioactive conformation oriented in the active site of
enzyme. Moreover, the 1,4-dimethoxybenzene ring oxygen and
the nitrogen atom bonded with this ring system made hydrogen
bond contacts with Phe31 and amide of Asn64. The pyridine
group of ML00100 has also formed hydrophobic interactions with
the carbonyl of Val115 (3.897 Å), and hydroxyl of Tyr121
(3.732 Å). On the whole, this compound has gained significant
hydrophobic interactions at both the active sites.
Binding Mode of SPB07954
This compound has scored the GOLD fitness scores of 81.509
for hTS binding and 76.042 for hDHFR binding. Binding at the
active site of hTS revealed that considerable interactions are
formed between SPB07954 and important residues Trp109,
Figure 7. Chemical structures of identified hits for dual inhibition and their overlay on pharmacophore model (Dual_Pharma).
doi:10.1371/journal.pone.0060470.g007
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Arg50, Asp215, Ser216, Asp218, Gly222, and Tyr258 (Figure 9).
A vital hydrophobic interaction was formed between the tert-
butylbenzene ring system of SPB07954 and indole moiety of
Trp109. Moreover, nitrogen atoms of triazole ring exhibited
hydrogen bond interactions with Asp218 (2.321 Å, 2.627 Å), and
Ser216 (3.201 Å) residues. The central sulfur atom of the
SPB07954 compound was also involved in interactions with the
hydroxyl group of Tyr258 (3.143 Å), and Ser216 (2.520 Å). On
the whole, numerous key interactions were observed between
SPB07954 and binding pocket residues of hTS. In terms of
hDHFR, SPB07954 illustrated various kind of interactions such as
p…p, p…s, and hydrogen bonding interactions with the important
residues like Ile7, Phe31, Ile60, Asn64, Val115, and Tyr121. The
tert-butylbenzene ring of SPB07954 is involved in crucial p…p,
p…s interactions with the phenyl ring of key residue Phe31. These
interactions instigated the SPB07954 compound to gain a proper
bioactive conformation positioned in the binding pocket of
enzyme. The central triazole ring system formed hydrogen
Figure 8. Binding modes of (A) compound 2 from the training set (B) overlay of all three dual hit compounds in the active site of
hTS. (C) compound 1 from the training set, and (D) overlay of all three dual hit compounds in the active site of hDHFR. Key protein residues and
ligands are represented by thick sticks. Hydrogen atoms have been removed for clarity.
doi:10.1371/journal.pone.0060470.g008
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Figure 9. Binding modes of all three dual hit compounds in the active sites of hTS and hDHFR. Key protein residues and hit compounds
are represented by thick sticks. Hydrogen atoms have been removed for clarity.
doi:10.1371/journal.pone.0060470.g009
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bonding with the Ile60 (3.411 Å, 3.193 Å). Whereas, one of the
carbonyl group formed hydrogen bond contact with amide of
Leu22. Moreover, methoxypropane moiety formed various
hydrophobic contacts with the backbone of Ile7 (2.818 Å),
Val115 (3.282 Å), and Tyr121 (3.506 Å).
Binding Mode of HTS07361
HTS07361was predicted with top GOLD fitness scores of
82.371 and 72.698 for hTS and hDHFR, respectively. In case of
hTS binding, this compound revealed a network of interactions
with important residues like Arg50, Trp109, Ser216, Asp218,
Gly222, and Tyr258 (Figure 9). The oxygen atom of piperidine-4-
carboxylate ring system formed key hydrophobic interaction with
the indole moiety of Trp109. Both the oxygen atoms of the
sulfonyl group anchored with piperidine-4-carboxylate ring of
HTS07361 compound are engaged in short-ranged hydrogen
bond interactions with Asp218 (1.731 Å, 3.256 Å), and Gly222
(3.342 Å). While, sulfur atom of thiophene ring and the oxygen
atoms of another sulfonyl group of HTS07361 have also formed
numerous strong hydrogen bonding interactions with amide
groups of Arg50 (2.174 Å, 3.073 Å) and Arg215 (1.563 Å,
2.921 Å), hydroxyl of Ser216 (2.147 Å), amide of Asp218
(3.768 Å), and hydroxyl of Tyr258 (3.737 Å). The elucidation of
binding mode of HTS07361 for hDHFR exhibited several
interactions with the active site residues like Ile7, Phe31, Phe34,
Asn64, Val115, and Tyr121.The imperative p…p interactions
Figure 10. GOLD fitness scores, AutoDock binding energies, and SYLVIA synthetic accessibility scores of top 8 optimized hit
compounds.
doi:10.1371/journal.pone.0060470.g010
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between the phenyl rings of HTS07361 and Phe34 were also
observed. This aromatic stacking seems to play a decisive role for
proper orientation of HTS07361 in the binding pocket. The same
phenyl group of this hit compound is also embroiled in close
hydrogen bonding to the CO of Ile7 (2.615 Å), Val115 (2.169 Å),
and hydroxyl of Tyr121 (3.056 Å). Moreover, the oxygen atoms of
the sulfonyl group affixed with piperidine-4-carboxylate ring of
HTS07361 compound have also formed significant hydrophobic
interactions with Phe31, and Asn64 in the active site region.
In summary, the interactions exhibited by the three dual hits are
analogous to the key interactions of experimentally known dual
inhibitors of hTS and hDHFR at the active site regions of the
target enzymes [33–36,44].
Optimization Studies
The top dual hit ML00100 of hTS and hDHFR was subjected
for further optimization studies. Diverse substitutions were made
in its structure with the aim of improving its binding affinity
towards the catalytically active amino acids. The optimized hits
were docked into the active sites of hTS and hDHFR using GOLD
program with the same parameters used to dock the direct
database hits. The binding modes of optimized hit compounds
were analyzed for molecular interactions with the essential amino
acids like Trp109, Arg50, Asp215, Ser216, Asp218, Gly222, and
Tyr258 at hTS binding site. In terms of hDHFR, binding mode
analysis was made to ensure that optimized hits hold imperative
interactions with key residues like Ile7, Leu22, Phe31, Phe34,
Ile60, pro61, Asn64, Val115, and Tyr121. Furthermore, the
binding energies of the optimized hits at the active sites of both
hTS and hDHFR enzymes were also calculated using Autodock.
These optimized compounds were further mapped to Dual_-
Pharma generated from experimentally known potent dual
inhibitors of hTS and hDHFR enzymes. Finally, top eight
optimized hits which showed maximum GOLD fitness scores
and lowest binding energies for both targets along with high fit
value for Dual_Pharma were also selected as final hits for dual
inhibition of hTS and hDHFR along with direct database hits
(Figure 10). As last step of our dual inhibition strategy, the
synthetic accessibility of the final 8 optimized hits was measured
using SYLVIA 1.0 program. The SYLVIA score for most of the
final optimized hits illustrates that these compounds are easy to be
synthesized.
Conclusion
We developed a novel computational approach by integrating
the affinity predictions from structure-based virtual screening with
dual ligand-based common feature pharmacophore to discover
potential dual inhibitors of hTS and hDHFR as antitumor agents.
As first step, a druglike database was prepared and was utilized to
perform dual-target docking studies. From results of docking
studies, compounds which formed strong interactions at the active
site for both target proteins were identified and selected for further
evaluation. Furthermore, a common feature pharmacophore
model was developed from experimentally known dual inhibitors
of hTS and hDHFR. This pharmacophore was mapped over the
compounds which were identified through dual-target docking
studies. The pharmacophore mapping procedure not only
facilitated us in eliminating the compounds which do not possess
basic chemical features necessary for dual inhibition of target
enzymes, but, also helped us to evade the difficulty stemmed from
overestimation of the affinity of weak binders producing false
positives during docking studies. Moreover, binding energies of the
selected possible dual hits were also calculated using AutoDock as
a cross-validation to the GOLD predictions. Finally, three
structurally diverse hit compounds that showed key interactions
at both the active sites, fit well upon the dual ligand-based
pharmacophore model, and exhibit lowest binding energies were
regarded as final hits for dual inhibition of hTS and hDHFR. In
addition, optimization studies were performed for a final dual hit
compound and eight optimized dual hits demonstrating excellent
binding features at target protein systems were developed.
Synthetic accessibility of developed optimized hits was also
computed using SYLVIA. The possible dual inhibitors along with
optimized hits may find clinical utility as antitumor, antimicrobial,
and antiprotozoal agents. On the whole, the strategy used in the
current study could be a promising computational approach and
may be generally applicable to other dual target drug designs.
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